Galapagos announces expanded relationship with AstraZeneca
BioFocus DPI to provide drug discovery services to US-site
This announcement marks the third collaboration between AstraZeneca and BioFocus DPI. In August 2006, Galapagos announced BioFocus DPI's first drug discovery collaboration with AstraZeneca. Under a second program initiated in April 2007, BioFocus DPI is performing chemistry and supporting biology and ADME services for an AstraZeneca hit-to-lead program. While these collaborations focused on AstraZeneca's European-based R&D, the new agreement announced expands BioFocus DPI's drug discovery services to AstraZeneca's US-based R&D.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.